Cargando…
Prolotherapy agent P2G is associated with upregulation of fibroblast growth factor-2 genetic expression in vitro
PURPOSE: Osteoarthritis (OA) is a prevalent, progressively degenerative disease. Researchers have rigorously documented clinical improvement in participants receiving prolotherapy for OA. The mechanism of action is unknown; therefore, basic science studies are required. One hypothesized mechanism is...
Autores principales: | Johnston, Elisha, Emani, Chandrakanth, Kochan, Andrew, Ghebrehawariat, Kidane, Tyburski, John, Johnston, Michael, Rabago, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719583/ https://www.ncbi.nlm.nih.gov/pubmed/33280075 http://dx.doi.org/10.1186/s40634-020-00312-z |
Ejemplares similares
-
Correction to: Prolotherapy agent P2G is associated with upregulation of fibroblast growth factor-2 genetic expression in vitro
por: Johnston, Elisha, et al.
Publicado: (2020) -
Prolotherapy injections and physiotherapy used singly and in combination for lateral epicondylalgia: a single-blinded randomised clinical trial
por: Yelland, Michael, et al.
Publicado: (2019) -
Prolotherapy: Regenerative Medicine for Lateral Epicondylitis
por: Piraccini, Emanuele, et al.
Publicado: (2020) -
Hypertonic dextrose injections (prolotherapy) in the treatment of symptomatic knee osteoarthritis: A systematic review and meta-analysis
por: Sit, Regina WS, et al.
Publicado: (2016) -
P02.23. The efficacy of prolotherapy using dextrose-morrhuate for lateral epicondylosis: a pilot randomized controlled trial
por: Rabago, D, et al.
Publicado: (2012)